Daiichi Sankyo to Commercialize Amgen’s 9 Investigational Biosimilars Including Adalimumab in Japan

Daiichi Sankyo announced on July 14 that the company has entered into an exclusive deal with Amgen for commercializing the US company’s nine investigational biosimilars in Japan. Of these nine products, three products, biosimilars of adalimumab, bevacizumab, and trastuzumab, are...read more